12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Amitiza lubiprostone: Phase III started

Sucampo began a placebo-controlled, U.S. and European Phase III trial to evaluate twice-daily 24 µg lubiprostone for 12 weeks in 420 patients. Sucampo and Takeda market lubiprostone as Amitiza in the U.S....

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >